CCM
SIOX

Cadian Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Cadian Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-31,250
Closed -$1.32M – 32
2017
Q4 		$1.32M Hold
31,250
– – 0.08% 24
2017
Q3 		$1.72M Buy
+31,250
New +$5.27M 0.08% 42

Other funds holding SIOX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Cadian Capital Management's SIOX Position: Q1 2018 in Review

Cadian Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2018, closing a stake of 31,250 shares — an estimated $1.32M sold.

Cadian Capital Management first reported a position in SIOX in Q3 2017 and held it in 2 quarters. The position peaked at $1.72M in Q3 2017. 81 funds tracked by Wall St. Rank hold SIOX as of Q1 2018.

  • Cadian Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Cadian Capital Management sold 31,250 Sio Gene Therapies Inc. Common Stock shares in Q1 2018, an estimated $1.32M.
  • Cadian Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Cadian Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $1.72M in Q3 2017.
  • 81 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2018.

Based on Cadian Capital Management's 13F filing for Q1 2018, filed 14 May 2018.